More Cell, Gene Therapy Firms Benefit From Korea R&D Grants
Support Breakdown Indicates Key R&D Areas
An analysis of the Korea Drug Development Fund’s selection of projects for R&D grants so far this year shows more applications and particular support for domestic cell and gene therapy projects, reflecting the strong interest in this area globally.
You may also be interested in...
Korea Drug Development Fund CEO H. Samuel Muk talks to Scrip how the government agency has evolved to support the Korean biopharma industry’s R&D and business development activities, as well as what key new projects are underway.
Scrip takes a look at the increasingly competitive landscape of Korean antibody-drug conjugate developers, which are now vying to catch up with their global rivals in the hot area.
The Pink Sheet’s roundup of key regulatory issues in Korea for 2022 and outlook for this year.